Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 5Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hemangiosarcoma 1HER2-positive Metastatic Breast Cancer 1HER2-Positive Primary Breast Cancer 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Radiosurgery 9Temozolomide 8Magnetic Resonance Spectroscopy 5pembrolizumab 4Specimen Handling 4Nivolumab 4Bevacizumab 4Receptors, Interleukin-8B 3Memantine 3trastuzumab deruxtecan 2abemaciclib 2Watchful Waiting 2Surveys and Questionnaires 2Radiotherapy 2Radiation 2Mental Status and Dementia Tests 2Ipilimumab 2Biopsy 2sotorasib 1sapanisertib 1sacituzumab govitecan 1ribociclib 1pertuzumab 1osimertinib 1lenvatinib 1fluciclovine F-18 1entrectinib 1elacestrant 1dexamethasone acetate 1dexamethasone 21-phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Ado-Trastuzumab Emtansine × 30 days × Clear all
NCT05593094 2026-05-26

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Hoffmann-La Roche

Phase 1/2 Active not recruiting
210 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡